multiple sclerosis. Multiple sclerosis
Conditions
Interventions
Intervention 1: Intervention group: intervention group will receive two nano-crocin capsules which contain 0.27 mg of nano-crocin every day for 12 weeks. Intervention 2: Control group: placebo group w
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: • Willingness to participate in the study• Age range between 18 to 60 years old Diagnosis of relapse remission multiple sclerosis according to the McDonalds 2010 criteria and taking B-interferon as treatment Diagnosis of mild to moderate according to DSM V(Diagnostic and Statistical Manual of Mental Disorders, 5th edition) by a neurologist and Beck Depression Inventory (BDI-II) (score from 11 to 20) EDSS lower than 5.5
Exclusion criteria
Exclusion criteria: Pregnancy (or having a planned pregnancy) or Lactation Allergy or sensibility to the drugs at the beginning of their treatments History of allergy or sensibility to Saffron or its components Receiving IVIG during the last six months of treatment Increase of liver enzymes three times more than normal value Stop taking drugs for more than forth months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Minimal Assessment of Cognitive Function in MS (MACFIMS) total score. Timepoint: baseline. Method of measurement: after 12-week intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| Total score of beck's depression inventory. Timepoint: baseline. Method of measurement: after 12-week intervention. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Soodeh Razeghi Jahromi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed